Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 8/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712348 | 0.93 | NAMPT (0.52) | HPGDGAANAMPTRIPK1SLC22A12 | |
| SCHEMBL8193162 | 0.86 | NAMPT (0.51) | NAMPT | |
| SCHEMBL14970362 | 0.85 | NOTUM (0.63) | HPGDGAANAMPTRIPK1SLC22A12 | |
| SCHEMBL30445878 | 0.85 | HPGD (0.50) | HPGDGAANAMPTRIPK1SLC22A12 | |
| SCHEMBL19722598 | 0.85 | HPGD (0.50) | HPGDGAANAMPTRIPK1SLC22A12 | |
| SCHEMBL24797633 | 0.81 | NAMPT (0.49) | HPGDGAANAMPT | |
| SCHEMBL16219054 | 0.81 | NAMPT (0.57) | HPGDGAANAMPTSLC22A12 | |
| SCHEMBL15998879 | 0.81 | NAMPT (0.57) | HPGDGAANAMPT | |
| SCHEMBL2563590 | 0.80 | ADRA1A (0.46) | NAMPT | |
| SCHEMBL18205136 | 0.79 | NAMPT (0.47) | HPGDGAANAMPTSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116194456-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | HPGD 340/4885GAA 3724/4885NAMPT 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.